1,061 Shares in Cencora, Inc. (NYSE:COR) Bought by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,061 shares of the company’s stock, valued at approximately $239,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Fisher Asset Management LLC purchased a new stake in shares of Cencora in the fourth quarter worth about $244,000. Trust Co. of Vermont bought a new position in shares of Cencora during the 4th quarter valued at approximately $62,000. Wahed Invest LLC bought a new stake in Cencora in the fourth quarter worth $567,000. Vanguard Group Inc. bought a new stake in Cencora in the fourth quarter worth $4,212,508,000. Finally, Hennessy Advisors Inc. purchased a new stake in Cencora during the fourth quarter valued at $3,307,000. 97.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the sale, the insider now directly owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gina Clark sold 27,093 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $216.07, for a total transaction of $5,853,984.51. Following the completion of the sale, the executive vice president now directly owns 15,158 shares of the company’s stock, valued at approximately $3,275,189.06. The disclosure for this sale can be found here. Insiders have sold 6,337,283 shares of company stock worth $1,476,300,791 in the last ninety days. 15.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on COR. Wells Fargo & Company boosted their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Robert W. Baird upped their price objective on Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. SVB Leerink reiterated an “outperform” rating and issued a $275.00 target price on shares of Cencora in a report on Thursday, June 27th. StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday. Finally, Citigroup lifted their price objective on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $249.63.

Cencora Trading Down 0.6 %

Shares of NYSE:COR traded down $1.43 on Tuesday, hitting $239.82. 1,150,774 shares of the company’s stock were exchanged, compared to its average volume of 1,396,652. The stock has a market capitalization of $47.83 billion, a price-to-earnings ratio of 26.24, a price-to-earnings-growth ratio of 1.68 and a beta of 0.45. Cencora, Inc. has a 12 month low of $171.65 and a 12 month high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.53. The business’s 50 day simple moving average is $229.77 and its two-hundred day simple moving average is $231.65.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The company had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter last year, the business posted $2.92 EPS. Analysts anticipate that Cencora, Inc. will post 13.56 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 26th. Investors of record on Friday, August 9th will be paid a $0.51 dividend. The ex-dividend date of this dividend is Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.85%. Cencora’s dividend payout ratio (DPR) is currently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.